Vyrologix shows impressive results in Covid-19 patients

CYTODYN Inc., a late-stage biotechnology company developing C-C chemokine receptor type 5 (CCR5) inhibiting drug leronlimab- Vyrologix, showed impressive results in improving the immune function of critically ill Covid-19 patients in the US.

Leronlimab-Vyrologix is a humanized monoclonal antibody drug used to treat human immunodeficiency virus. It is a CCR5 antagonist that protects healthy T cells from viral infection. The CCR5 receptor plays a crucial role in modulating immune cell trafficking to sites of inflammation. Because of the drug’s ability to mitigate the cytokine storm, which is common in Covid-19 fatalities, it has become the basis for its study as a potential Covid-19 treatment.